These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29061751)

  • 1. Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects.
    Toyama K; Furuie H; Ishizuka H
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.
    Ishizuka H; Toyama K; Yoshiba S; Okabe H; Furuie H
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3873-8. PubMed ID: 22526307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza.
    Kashiwagi S; Watanabe A; Ikematsu H; Uemori M; Awamura S;
    Clin Infect Dis; 2016 Aug; 63(3):330-7. PubMed ID: 27118785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection.
    Yoshihara K; Ishizuka H; Kubo Y
    Drug Metab Pharmacokinet; 2013; 28(5):416-26. PubMed ID: 23574886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial.
    Kashiwagi S; Watanabe A; Ikematsu H; Awamura S; Okamoto T; Uemori M; Ishida K
    J Infect Chemother; 2013 Aug; 19(4):740-9. PubMed ID: 23732307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.
    Sugaya N; Ohashi Y
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2575-82. PubMed ID: 20368393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced pneumonitis following the administration of laninamivir octanoate: The first two reported cases.
    Ogawa T; Tanaka K; Ohgino K; Omori N; Betsuyaku T; Sayama K
    J Infect Chemother; 2019 Dec; 25(12):1043-1046. PubMed ID: 31178281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
    Panozzo J; Oh DY; Margo K; Morton DA; Piedrafita D; Mosse J; Hurt AC
    Antiviral Res; 2015 Aug; 120():66-71. PubMed ID: 26022199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers.
    Ishizuka H; Yoshiba S; Okabe H; Yoshihara K
    J Clin Pharmacol; 2010 Nov; 50(11):1319-29. PubMed ID: 20145259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics.
    Sunagawa S; Higa F; Cash HL; Tateyama M; Uno T; Fujita J
    Influenza Other Respir Viruses; 2013 Jan; 7(1):1-3. PubMed ID: 22405585
    [No Abstract]   [Full Text] [Related]  

  • 12. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition.
    Vavricka CJ; Li Q; Wu Y; Qi J; Wang M; Liu Y; Gao F; Liu J; Feng E; He J; Wang J; Liu H; Jiang H; Gao GF
    PLoS Pathog; 2011 Oct; 7(10):e1002249. PubMed ID: 22028647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
    Koyama K; Nakai D; Takahashi M; Nakai N; Kobayashi N; Imai T; Izumi T
    Drug Metab Dispos; 2013 Jan; 41(1):180-7. PubMed ID: 23091189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males.
    Shida Y; Hara K; Nohda S; Soutome T; Hirama T
    J Clin Pharm Ther; 2013 Jun; 38(3):236-40. PubMed ID: 23489210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.
    Ishizuka H; Yoshiba S; Yoshihara K; Okabe H
    J Clin Pharmacol; 2011 Feb; 51(2):243-51. PubMed ID: 20197485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of bioactivating enzymes involved in the hydrolysis of laninamivir octanoate, a long-acting neuraminidase inhibitor, in human pulmonary tissue.
    Koyama K; Ogura Y; Nakai D; Watanabe M; Munemasa T; Oofune Y; Kubota K; Shinagawa A; Izumi T
    Drug Metab Dispos; 2014 Jun; 42(6):1031-8. PubMed ID: 24682756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuraminidase inhibitors for preventing and treating influenza in children.
    Wang K; Shun-Shin M; Gill P; Perera R; Harnden A
    Cochrane Database Syst Rev; 2012 Jan; 1():CD002744. PubMed ID: 22258949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
    Samson M; Abed Y; Desrochers FM; Hamilton S; Luttick A; Tucker SP; Pryor MJ; Boivin G
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5220-8. PubMed ID: 24957832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate for Inhalation Suspension Set in children under the age of 5 in a post-marketing surveillance.
    Nakano T; Yamaguchi H; Chiba T; Shiosakai K; Chikada S; Matsuoka Y
    J Infect Chemother; 2021 Oct; 27(10):1436-1446. PubMed ID: 34226112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled Laninamivir Octanoate as Prophylaxis for Influenza in Children.
    Nakano T; Ishiwada N; Sumitani T; Uemori M; Isobe K;
    Pediatrics; 2016 Dec; 138(6):. PubMed ID: 27940664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.